Back to results
US 8,283,321 B2Granted
Kallikrein-binding “Kunitz domain” proteins and analogues thereof
AssigneeDyax Corp.
InventorsWilliam Markland, Robert C. Ladner
Life of this patent
Estimating the term…
Abstract
This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
Claims12
A pharmaceutical composition comprising a kallikrein inhibiting protein and a pharmaceutically acceptable carrier,
- wherein the kallikrein inhibiting protein comprises a non-naturally occurring Kunitz domain, said Kunitz domain having disulfide bonds at Cys5-Cys55, Cys14-Cys38, and Cys30-Cys51 and further having:
- amino acid number 13 selected from the group consisting of His and Pro;
- amino acid number 14 as Cys;
- amino acid number 16 selected from the group consisting of Ala and Gly;
- amino acid number 17 selected from the group consisting of Ala, Asn, and Ser;
- amino acid number 18 selected from the group consisting of His and Leu;
- amino acid number 19 selected from the group consisting of Gln, Leu, and Pro;
- amino acid number 31 as Glu;
- amino acid number 32 selected from the group consisting of Glu and Gln;
- amino acid number 34 selected from the group consisting of Ser, Thr, and Ile;
- and
- amino acid number 39 selected from the group consisting of Gly, Glu, and Ala,
- wherein the above amino acids are numbered to correspond to the numbering of amino acid residues of bovine pancreatic trypsin inhibitor (BPTI) (SEQ ID NO:1), and wherein the kallikrein inhibiting protein binds plasma kallikrein with a Ki less than 500 pM.
10 more elements
Dependencies are inferred from the claim text.